Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that one of the USN’s contract manufacturer named as Azochem Laboratories had placed another purchase order for Phytofare® Complex.
The exclusive deal between the two entities will help USN to restrict the input costs related to production, while improving product effectiveness by substituting the currently used generic green tea extracts in its lineup of market-leading products, with the Phytofare® Catechin Complex. USN comes in the list of international health and nutrition supplement offering brand that have their reach in over 50 countries. The entity was established in South Africa some fifteen years ago.
Metabolix, Inc. (NASDAQ:MBLX) Reports 2Q2015 Results
Metabolix, Inc. (NASDAQ:MBLX) posted a net loss of $6.1 million from continuing operations in 2Q2015 compared to $6.8 million in the prior year period. Joseph Shaulson, the CEO and President said that in June, they completed a private placement to raise $15 million in capital. The company will be using this funds to execute business plans with a focus on converting commercial development plans to enhance sales Mirel specialty biopolymers.
The CEO added that Metabolix have ended the capital expansion of its pilot recovery center for Mirel PHA biopolymers. Also, they have started biopolymer recovery activities with fermentation broth manufactured earlier this year. In 3Q2015, they expect to ramp up the production to company’s new nameplate capacity along with new U.S. supplier.
CTI Industries Corp. (NASDAQ:CTIB) Reports 2Q2015 Financial Results
CTI Industries Corp. (NASDAQ:CTIB) 2Q2015 net income came at $52,000 compared to a net loss of $122,000 in 2Q2014. For 1H2015, net Income stood at $336,000 against net loss of $77,000 in the comparable period, a year earlier. The EBITDA was up 62% for 2Q2015 and came at $918,000 compared to $568,000 in 2Q2014.
On Tuesday’s trading session, the share price of Plandai gained more than 2% to close the trading session at $0.143.
